OneMedNet Corp (ONMDW) shareholders
ONMDWNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31Also trades as ONMD
$0.02+0.00 (0.00%)
Close on Oct 30, 2026Market cap $250.19MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
5M
Shares held, 13F filers
Institutional holders
10
1 new, 2 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
12 buys · 1 sales
Net bought $3.12M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Off the Chain LP Joint filing with Off the Chain Capital, LLC (9.50%) | 3,215,650 | 9.50% | 13G (passive) | Sep 25, 2024 |
| Td Securities (USA) LLC | 3,025,338 | 6.20% | 13G (passive) amendment | Sep 30, 2025 |
| Cowen and Company, LLC | 2,970,836 | 9.50% | 13G (passive) | Sep 30, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ONMDW | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Toronto Dominion Bank | 2,914,096 | – | $101.99K | +3,945 | 0.00% |
| Savant Capital, LLC | 871,744 | – | $30.95K | New | 0.00% |
| D. E. Shaw & Co., Inc. | 420,000 | – | $15.20K | – | 0.00% |
| Yakira Capital Management, Inc. | 330,494 | – | $11.47K | – | 0.00% |
| Polar Asset Management Partners Inc. | 256,916 | – | $9.07K | – | 0.00% |
| Rivernorth Capital Management, LLC | 128,631 | – | $4.63K | – | 0.00% |
| Clear Street Group Inc. | 83,747 | – | $2.91K | – | 0.00% |
| Whitebox Advisors LLC | 49,700 | – | $1.73K | – | 0.00% |
| Two Sigma Securities, LLC | 19,086 | – | $658 | −2,900 | 0.00% |
| UBS Group AG | 1,984 | – | $69 | −700 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 10 | 5M | 1 / 1 | 2 / 2 | 1M | 0M |
| Q1 2026 | 13 | 5M | 3 / 2 | 2 / 0 | 1M | 0M |
| Q4 2025 | 10 | 4M | 1 / 0 | 4 / 4 | 0M | 1M |
| Q3 2025 | 13 | 6M | 3 / 2 | 2 / 0 | 1M | 0M |
| Q2 2025 | 12 | 5M | 2 / 1 | 1 / 2 | 3M | 0M |
| Q1 2025 | 12 | 2M | 0 / 0 | 2 / 2 | 0M | 0M |
| Q4 2024 | 14 | 2M | 1 / 3 | 1 / 5 | 0M | 4M |
| Q3 2024 | 18 | 6M | 0 / 3 | 6 / 2 | 1M | 0M |
| Q2 2024 | 20 | 5M | 2 / 2 | 7 / 2 | 1M | 1M |
| Q1 2024 | 20 | 5M | 1 / 3 | 2 / 1 | 0M | 0M |
| Q4 2023 | 20 | 4M | 20 / 0 | 0 / 0 | 4M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Jeffrey Yu | Chief Medical Officer, Director, 10% owner | 10,235,237 | Sep 14, 2026 |
| Aaron Green | Chief Executive Officer, Director | 1,896,375 | Jun 24, 2026 |
| Thomas Kosasa | Director, 10% owner | 18,538,150 | Aug 7, 2026 |
| Robert Lawrence Golden | Director | 547,905 | Nov 26, 2025 |
| Jair Clarke | Director | 138,485 | Nov 26, 2025 |
| Sherry Coonse McCraw | Director | 56,342 | Nov 26, 2025 |
| Eric Casaburi | Director | 110,475 | Nov 26, 2025 |
| Kenneth Alleyne | Director | 38,219 | Nov 26, 2025 |
| Andrew B. Zeinfeld | Director | 381,525 | Nov 26, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jeffrey Yu Chief Medical Officer, Director, 10% owner | Sep 10, 2026 | Buy | +142,857 | $0.63 | $90.00K | 8,923,267 |
| Thomas Kosasa Director, 10% owner | Jul 30, 2026 | Buy | +1,449,275 | $0.69 | $1,000.00K | 18,538,150 |
| Aaron Green Chief Executive Officer, Director | Jun 23, 2026 | Buy | +36,650 | $0.57 | $20.89K | 1,896,375 |
| Jeffrey Yu Chief Medical Officer, Director, 10% owner | Jun 23, 2026 | Buy | +158,730 | $0.63 | $100.00K | 8,780,410 |
| Jeffrey Yu Chief Medical Officer, Director, 10% owner | Jun 16, 2026 | Buy | +172,414 | $0.58 | $100.00K | 8,621,680 |
| Aaron Green Chief Executive Officer, Director | Jun 15, 2026 | Buy | +18,702 | $0.54 | $10.10K | 1,859,725 |
| Aaron Green Chief Executive Officer, Director | Jun 12, 2026 | Buy | +36,920 | $0.56 | $20.68K | 1,841,023 |
| Thomas Kosasa Director, 10% owner | Jun 12, 2026 | Buy | +158,730 | $0.63 | $100.00K | 17,088,874 |
| Thomas Kosasa Director, 10% owner | May 18, 2026 | Buy | +268,817 | $0.93 | $250.00K | 16,930,144 |
| Thomas Kosasa Director, 10% owner | Apr 23, 2026 | Buy | +280,898 | $0.89 | $250.00K | 16,661,327 |
| Jeffrey Yu Chief Medical Officer, Director, 10% owner | Apr 1, 2026 | Award | +219,429 | $0.83 | $182.13K | 8,449,266 |
| Jeffrey Yu Chief Medical Officer, Director, 10% owner | Apr 1, 2026 | Buy | +903,614 | $0.83 | $750.00K | 8,229,837 |
| Thomas Kosasa Director, 10% owner | Feb 6, 2026 | Buy | +595,238 | $0.84 | $500.00K | 16,380,429 |
| Eric Casaburi Director | Nov 26, 2025 | Award | +45,000 | – | – | 110,475 |
| Kenneth Alleyne Director | Nov 26, 2025 | Award | +38,219 | – | – | 38,219 |
| Jair Clarke Director | Nov 26, 2025 | Award | +45,000 | – | – | 138,485 |
| Jeffrey Yu Chief Medical Officer, Director | Nov 26, 2025 | Award | +45,000 | – | – | 7,326,223 |
| Sherry Coonse McCraw Director | Nov 26, 2025 | Award | +45,000 | – | – | 56,342 |
| Thomas Kosasa Director | Nov 26, 2025 | Award | +45,000 | – | – | 15,785,191 |
| Andrew B. Zeinfeld Director | Nov 26, 2025 | Award | +45,000 | – | – | 381,525 |
| Aaron Green Chief Executive Officer, Director | Nov 26, 2025 | Award | +45,000 | – | – | 1,930,425 |
| Robert Lawrence Golden Chief Financial Officer, Director | Nov 26, 2025 | Award | +45,000 | – | – | 547,905 |
| Jeffrey Yu Chief Medical Officer, Director | Nov 24, 2025 | Award | +200,000 | – | – | 7,281,223 |
| Aaron Green Chief Executive Officer, Director | Nov 24, 2025 | Award | +1,000,000 | – | – | 1,885,425 |
| Robert Lawrence Golden Chief Financial Officer, Director | Nov 24, 2025 | Award | +33,333 | – | – | 502,905 |
| Robert Lawrence Golden Chief Financial Officer, Director | Nov 24, 2025 | Award | +300,000 | – | – | 469,572 |
| Aaron Green Chief Executive Officer, Director | Nov 18, 2025 | Sale | −61,555 | $1.20 | $73.87K | 1,804,103 |
| Aaron Green Chief Executive Officer, Director | Oct 22, 2025 | Sale | −64,767 | $2.23 | $144.43K | 1,865,658 |
| Eric Casaburi Director | Oct 15, 2025 | Buy | +10,000 | $3.05 | $30.50K | 65,475 |
| Jeffrey Yu Chief Medical Officer, Director | Sep 25, 2025 | Buy | +1,250 | $1.03 | $1.29K | 7,081,223 |
| Jeffrey Yu Chief Medical Officer, Director | Sep 24, 2025 | Buy | +17,200 | $1.02 | $17.54K | 7,079,973 |
| Thomas Kosasa Director | Sep 24, 2025 | Buy | +6,000 | $0.93 | $5.58K | 15,740,191 |
| Jeffrey Yu Chief Medical Officer, Director | Sep 23, 2025 | Buy | +5,700 | $0.93 | $5.30K | 7,062,773 |
| Jeffrey Yu Chief Medical Officer, Director | Sep 22, 2025 | Buy | +400 | $0.95 | $380 | 7,057,073 |
| Jeffrey Yu Chief Medical Officer, Director | Sep 19, 2025 | Buy | +1,250 | $0.89 | $1.11K | 7,056,673 |
| Jeffrey Yu Chief Medical Officer, Director | Sep 18, 2025 | Buy | +700 | $0.91 | $637 | 7,055,423 |
| Jeffrey Yu Chief Medical Officer, Director | Sep 5, 2025 | Buy | +2,100 | $0.86 | $1.81K | 7,054,723 |
| Jeffrey Yu Chief Medical Officer, Director | Sep 4, 2025 | Buy | +11,810 | $0.87 | $10.27K | 7,052,623 |
| Jeffrey Yu Chief Medical Officer, Director | Sep 3, 2025 | Buy | +11,670 | $0.81 | $9.45K | 7,040,813 |
| Jeffrey Yu Chief Medical Officer, Director | Sep 2, 2025 | Buy | +24,319 | $0.85 | $20.67K | 7,029,143 |
| Jeffrey Yu Chief Medical Officer, Director | Aug 29, 2025 | Buy | +10,890 | $0.82 | $8.93K | 7,004,824 |
| Thomas Kosasa Director | Aug 29, 2025 | Buy | +581,395 | $0.86 | $500.00K | 15,734,191 |
| Jeffrey Yu Chief Medical Officer, Director | Aug 28, 2025 | Buy | +17,000 | $0.80 | $13.60K | 6,993,934 |
| Jeffrey Yu Chief Medical Officer, Director | Aug 27, 2025 | Buy | +21,374 | $0.69 | $14.75K | 6,976,934 |
| Jeffrey Yu Chief Medical Officer, Director | Aug 26, 2025 | Buy | +173,350 | $0.69 | $119.61K | 6,955,560 |
| Jeffrey Yu Chief Medical Officer, Director | Aug 25, 2025 | Buy | +13,300 | $0.75 | $9.98K | 6,782,210 |
| Jeffrey Yu Chief Medical Officer, Director | Aug 21, 2025 | Buy | +15,000 | $0.77 | $11.55K | 6,768,910 |
| Jeffrey Yu Chief Medical Officer, Director | Aug 19, 2025 | Buy | +16,500 | $0.77 | $12.71K | 6,753,910 |
| Jeffrey Yu Chief Medical Officer, Director | Jun 20, 2025 | Buy | +1,666,666 | $0.42 | $700.00K | 6,737,410 |
| Thomas Kosasa Director | Jun 20, 2025 | Buy | +1,190,476 | $0.42 | $500.00K | 15,152,796 |
| Jeffrey Yu Chief Medical Officer, Director | Jun 19, 2025 | Conversion | +1,828,279 | $0.71 | $1.30M | 5,070,744 |
| Thomas Kosasa Director | Jun 19, 2025 | Conversion | +2,865,016 | $0.71 | $2.03M | 13,962,320 |
| Thomas Kosasa Director | Jun 19, 2025 | Conversion | +2,123,424 | $0.75 | $1.59M | 11,097,304 |
| Jeffrey Yu Chief Medical Officer, Director | Jun 17, 2025 | Conversion | +479,270 | $1.14 | $546.37K | 3,242,465 |
| Thomas Kosasa Director | Jun 17, 2025 | Conversion | +493,056 | $1.14 | $562.08K | 8,973,880 |
| Aaron Green Chief Executive Officer, Director | Jun 17, 2025 | Conversion | +240,425 | $1.14 | $274.08K | 885,425 |
| Thomas Kosasa Director | Jun 16, 2025 | Buy | +55,000 | $0.38 | $20.90K | 8,480,824 |
| Thomas Kosasa Director | Apr 21, 2025 | Buy | +47,000 | $0.49 | $23.03K | 8,425,824 |
| Robert Lawrence Golden Chief Financial Officer, Director | Jan 31, 2025 | Award | +24,272 | – | – | 169,572 |
| Jair Clarke Director | Jan 1, 2025 | Award | +82,143 | – | – | 93,485 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 15, 2026 (FINRA, reported twice a month)
Short % of shares outstanding
–
0M shares short
Days to cover
2.8
At 0M shares a day
Change since last report
-12.8%
From 0M shares
Short volume, 20 days
52.4%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of OneMedNet's stock actually held short. No settlement fails above the SEC's reporting threshold in the last 90 days.